Last update 21 Nov 2024

Glecirasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
戈来雷塞, 枸橼酸格来雷塞
+ [2]
Target
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationOrphan Drug (EU), Breakthrough Therapy (CN), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC31H26ClF4N7O2
InChIKeyQRRJEUIQLZNPIO-UHFFFAOYSA-N
CAS Registry2657613-87-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12C mutant Non-small Cell Lung CancerNDA/BLA
CN
06 May 2024
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
CN
18 Jul 2024
Pancreatic Ductal CarcinomaPhase 2
CN
14 Apr 2022
Small intestine carcinoma recurrentPhase 2
CN
17 Feb 2022
Appendiceal NeoplasmsPhase 2
CN
07 Feb 2022
Small intestine carcinomaPhase 2
CN
07 Feb 2022
Non-Small Cell Lung CancerPhase 2
US
03 Sep 2021
Advanced Malignant Solid NeoplasmPhase 2
CN
26 Jul 2021
Colorectal CancerPhase 2
CN
-
Pancreatic Ductal AdenocarcinomaPhase 2
CN
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
102
(zmrppemlte) = cynxfturls ceosqqweck (lzfblyvskv )
Positive
14 Sep 2024
Glecirasib plus JAB-3312
(PD-L1 TPS≥50%)
(zmrppemlte) = grxzamvbbp ceosqqweck (lzfblyvskv )
Phase 1/2
194
(jmnihvtgiy) = cqjwkmnphl jnprhnlszw (jcbalksjcr )
Positive
01 Jun 2024
(frontline)
(bvyehyodkv) = oqmfeexymx rcqgsiqyap (dviizumlrq )
Phase 1/2
179
(ftmuxuxrqs) = quazeqjgcm bsbpeqqcpz (qiahgynjgn )
Positive
24 May 2024
Phase 2
119
Glecirasib 800mg daily
(qfoevehhuj) = okkkzrfglm umoxzxtqea (dfcqqhrtsg )
Met
Positive
30 Apr 2024
Not Applicable
50
(iekqxrwmig) = pjkyjqeisx lmcvbrgsrf (exknrmthmr )
Positive
19 Jan 2024
Phase 1/2
48
(dqbiqwovjn) = qmpgpyechg dmwrmlpyem (gjbwhdcfek )
Positive
18 Jan 2024
Phase 1/2
60
(tfsfjxgzag) = cxhpzklfwv tvzlfrdwiy (sjlvndjlrc )
Positive
22 Oct 2023
(KRAS G12Ci naïve NSCLC)
(eklmemtjzc) = wwqvnlkmmg jhkovcbvqn (denijeisco )
Phase 1/2
82
(escguzhafa) = vtgozktgyk ekdbqbdlwj (lxrfjsxvkg )
Positive
25 Sep 2023
JAB-21822+西妥昔单抗
(escguzhafa) = umgnffmdzm ekdbqbdlwj (lxrfjsxvkg )
Phase 1/2
Non-Small Cell Lung Cancer
Second line
KRAS G12C
70
(ncpjqtotgp) = hpmnbatzuv xspnvzlrdo (hrzgljsldo )
Positive
25 Sep 2023
(ncpjqtotgp) = cpwyzxglgr xspnvzlrdo (hrzgljsldo )
Phase 1/2
Solid tumor
Second line
KRAS G12C
125
(ccgocrowdm) = pvaideoycj mviqlammtf (mecwxbzloa )
Positive
25 Sep 2023
(ccgocrowdm) = wuplpdsdtf mviqlammtf (mecwxbzloa )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free